Retrospective Study of Ceftazidime-Avibactam Treatment for Multidrug-Resistant Gram-Negative Bacterial Infections in King Chulalongkorn Memorial Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260114005

Enrollment

Registered

2026-01-14

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infections caused by aerobic gram-negative pathogens. carbapenem-resistant Enterobacteriaceae, multi-drug resistant gram-negative bacteria, mortality rate, ceftazidime-avibactam

Interventions

received more than 48 hours of ceftazidime-avibactam

Treatment

ceftazidime-avibactam

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient age more than 18 years old 2. Receipt of more than 48 hours of ceftazidime-avibactam.

Exclusion criteria

Exclusion criteria: 1. Death within 48 hours after initiate antibiotic.

Design outcomes

Primary

Measure	Time frame
All-cause mortality rate 14 days after initiate ceftazidime-avibactam Mortality rate	—

Secondary

Measure	Time frame
Clinical response 14 days after receipt ceftazidime-avibactam Clinical response rate	—

Countries

Thailand

Contacts

Public ContactKamonwan Jutivorakool

King Chulalongkorn Memorial Hospital

kamonwan.ju@chula.ac.th0649499551

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026